Stockscreener 앱 받기
1.36
14.47%
-0.23
시간 외 거래:
1.32
-0.04
-2.94%
Calidi Biotherapeutics Inc 주식(CLDI)의 최신 뉴스
Armistice Capital reports 4.99% Calidi Biotherapeutics (CLDI) stake in Schedule 13G/A - Stock Titan
Form 8K Calidi Biotherapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Calidi Biotherapeutics Reports Quarterly Results and Pipeline Progress - TipRanks
Calidi Biotherapeutics Q2 net loss narrows to $4.2M; G&A cuts 48% - scanx.trade
Calidi Biotherapeutics 2Q 2026: Net loss $4.16M, EPS $(2.94) — 10-Q Summary - TradingView
Calidi Biotherapeutics Reports Positive FDA Pre-IND Feedback for CLD-401, Showcases RedTail Platform Data and Cuts G&A Expenses - Quiver Quantitative
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance
Price to book forward of Calidi Biotherapeutics Inc. – OTC:CLDWW - TradingView
Price to sales forward of Calidi Biotherapeutics Inc. – OTC:CLDWW - TradingView
Calidi Biotherapeutics Inc (CLDI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Calidi Biotherapeutics (CLDI) Insider Trading Activity 2026 $CLDI - MarketBeat
Price to sales forward of Calidi Biotherapeutics, Inc. – BOATS:CLDI - TradingView
Calidi Biotherapeutics Inc. (NYSE: CLDI) Share Price, CLDI Stock News, CLDI Share Price & Updates - Kalkine
Calidi Biotherapeutics Announces Reverse Stock Split to Maintain NYSE American Listing – July 2026 8-K Filing - Minichart
Calidi Biotherapeutics Implements Reverse Stock Split on NYSE - TipRanks
Calidi Biotherapeutics Inc (CLDI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CLDI|Calidi Biotherapeutics Inc|Price:0.109|Chg%:+0.009 - TradingKey
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference - GlobeNewswire
Calidi Biotherapeutics Inc (CLDI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Calidi highlights new EpCam-targeting T-cell engager data - Stock Titan
Calidi Biotherapeutics Inc (CLDI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Calidi Biotherapeutics Inc (CLDI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Calidi Biotherapeutics Inc (CLDI) Cash Flow - TradingKey
Stock Splits Calendar for: - Yahoo! Finance Canada
TradingKey - TradingKey
Calidi Biotherapeutics Inc (CLDI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Calidi Biotherapeutics, Inc. (CLDI) stock price, news, quote and history - Yahoo Finance UK
Calidi Biotherapeutics To Carry Out 1-for-16 Reverse Stock Split On July 31st, 2026 - Moomoo
Calidi Gains on Company Update - Baystreet.ca
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers - The Manila Times
Calidi Cut G&A by About $1M; Targets First Dose in Q1 2027 - Stock Titan
Calidi Biotherapeutics to Effect 1-for-16 Reverse Stock Split - marketscreener.com
Calidi Announces Reverse Stk Split, Expected to Begin Trading on a 1-For-16 Split Adjusted Basis on July 31 - Moomoo
Calidi shareholders will get one share for every 16 held - Stock Titan
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 - Yahoo Finance
Calidi Biotherapeutics Plans Relocation Through New Lease Agreements - TipRanks
Calidi Biotherapeutics Signs 44-Month Lease at 5580 Morehouse Drive, San Diego for New Corporate Headquarters - Minichart
New lease could save Calidi Biotherapeutics (NYSE American: CLDI) $1.1M yearly - Stock Titan
Calidi Biotherapeutics (CLDI) Slides Over 8% as Stock Nears Critical Support Level at $0.11Volatility Breakout Picks - dars.gov.et
Calidi Biotherapeutics grants inducement options to new VP Finance - scanx.trade
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times
Calidi lures new finance chief with 100,000 stock options - Stock Titan
Calidi Biotherapeutics (CLDI) stock plunges 35% after hours — here's why - MSN
CLDI Q4 2025 Earnings: Surprise EPS Beat Signals Cost Discipline Amid Pre-Revenue PhaseTech Earnings Analysis - dars.gov.et
CLDI Q4 2025 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesRevenue Growth Report - dars.gov.et
Calidi Biotherapeutics (CLDI) director Sanders Corazon files initial Form 3 - Stock Titan
CLDI Q4 2025 Earnings: EPS Surprises with 73.6% Beat as Clinical Pipeline AdvancesAnalyst Consensus Shift - dars.gov.et
CLDI Q4 2025 Earnings: Narrower-than-expected loss boosts shares by 8.88%Low Growth Earnings - dars.gov.et
Calidi Biotherapeutics, Inc. Actuals & Estimates (AMEX:CLDI) - TradingView
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit - Sahm
Calidi’s tumor-targeted T-cell approach aims at hard-to-hit solid tumors - Stock Titan
Calidi Biotherapeutics presents data on T-cell activation approach - scanx.trade
Form 8K Calidi Biotherapeutics Inc For: 23 June By Investing.com - Investing.com Australia
Form 8K Calidi Biotherapeutics Inc For: 23 June - Investing.com UK
Calidi Biotherapeutics Expands Board With New Independent Director - TipRanks
Calidi Biotherapeutics Appoints Industry Veteran Corsee Sanders, Ph.D., to Board of Directors to Advance RedTail Platform and CLD-401 Clinical Development – Minichart - Minichart
Calidi Biotherapeutics appoints Corsee Sanders to board - Investing.com
Industry veteran Corsee Sanders joins Calidi Biotherapeutics (CLDI) board and Audit Committee - Stock Titan
Calidi Biotherapeutics appoints Corsee Sanders to board By Investing.com - Investing.com UK
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - The Manila Times
1.80%
1.77%
자본화:
|
볼륨(24시간):